Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Compugen Ltd. - Ordinary Shares (NQ:CGEN)

1.350 -0.010 (-0.74%)
Streaming Delayed Price Updated: 11:55 AM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 89,981
Open 1.360
Bid (Size) 1.350 (7)
Ask (Size) 1.360 (6)
Prev. Close 1.360
Today's Range 1.350 - 1.380
52wk Range 1.130 - 2.660
Shares Outstanding 86,433,432
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free
Via ACCESS Newswire
Compugen Ltd (NASDAQ:CGEN) Reports Q2 2025 Revenue and EPS Miss, Shares Drop in Premarket
Compugen Ltd (CGEN) misses Q2 2025 revenue and EPS estimates, shares drop 2% premarket. Weak financials and clinical progress concerns weigh on investor sentiment. 
Via Chartmill

Performance

YTD
-18.2%
-18.2%
1 Month
-12.9%
-12.9%
3 Month
-18.2%
-18.2%
6 Month
-14.6%
-14.6%
1 Year
-27.4%
-27.4%

More News

Read More
Earnings Scheduled For August 6, 2025
Via Benzinga
Earnings Scheduled For May 19, 2025
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Preview For Compugen
Via Benzinga
Uncovering Potential: Compugen's Earnings Preview
Via Benzinga
Earnings Scheduled For March 4, 2025
Via Benzinga
CGEN Stock Earnings: Compugen Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
CGEN Stock Earnings: Compugen Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
7 Speculative Stocks to Double Your Money THIS Year
Via InvestorPlace
Crude Oil Rises Over 1%; Biodexa Pharmaceuticals Shares Plunge
Via Benzinga
Topics Stocks
Earnings Scheduled For March 5, 2024
Via Benzinga
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Dow Jumps 150 Points; FactSet Shares Rise After Q1 Results
Via Benzinga
Topics Stocks
Compugen Ltd. (NASDAQ: CGEN) is One of Tuesday Morning’s Most Active Stocks
Via Investor Brand Network
Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today?
Via Benzinga
Why Are Stocks Up Today?
Via InvestorPlace
Why Is Compugen (CGEN) Stock Up 189% Today?
Via InvestorPlace
US Stocks Higher; Accenture Issues Weak Sales Outlook
Via Benzinga
Topics Stocks
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
From Gilead Sciences, Inc.
Via Business Wire
7 Promising Penny Stocks With the Potential to Defy Expectations
Via InvestorPlace
Use Support And Resistance Levels To Avoid Chaos In Your Portfolio
Via Talk Markets

Frequently Asked Questions

Is Compugen Ltd. - Ordinary Shares publicly traded?
Yes, Compugen Ltd. - Ordinary Shares is publicly traded.
What exchange does Compugen Ltd. - Ordinary Shares trade on?
Compugen Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Compugen Ltd. - Ordinary Shares?
The ticker symbol for Compugen Ltd. - Ordinary Shares is CGEN on the Nasdaq Stock Market
What is the current price of Compugen Ltd. - Ordinary Shares?
The current price of Compugen Ltd. - Ordinary Shares is 1.350
When was Compugen Ltd. - Ordinary Shares last traded?
The last trade of Compugen Ltd. - Ordinary Shares was at 09/18/25 11:55 AM ET
What is the market capitalization of Compugen Ltd. - Ordinary Shares?
The market capitalization of Compugen Ltd. - Ordinary Shares is 116.69M
How many shares of Compugen Ltd. - Ordinary Shares are outstanding?
Compugen Ltd. - Ordinary Shares has 117M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.